Novartis Reports Long-Term Outcomes for Kymriah in Pediatric ALL

Novartis today presented long-term follow-up data for Kymriah (tisagenlecleucel) in pediatric patients with relapsed or refractory B-cell acute lymphoblastic leukemia. The data showed that 35% of patients remained in remission at five years, with the majority of long-term responders achieving complete remission after a single infusion.